Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash & Current Investments (2017 - 2025)

Historic Cash & Current Investments for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $576.1 million.

  • Protagonist Therapeutics' Cash & Current Investments rose 2291.26% to $576.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $576.1 million, marking a year-over-year increase of 2291.26%. This contributed to the annual value of $418.9 million for FY2024, which is 2263.35% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Cash & Current Investments stood at $576.1 million for Q3 2025, which was up 2291.26% from $570.5 million recorded in Q2 2025.
  • Protagonist Therapeutics' Cash & Current Investments' 5-year high stood at $576.1 million during Q3 2025, with a 5-year trough of $192.6 million in Q2 2021.
  • Over the past 5 years, Protagonist Therapeutics' median Cash & Current Investments value was $320.8 million (recorded in 2023), while the average stood at $363.8 million.
  • In the last 5 years, Protagonist Therapeutics' Cash & Current Investments soared by 35413.03% in 2021 and then crashed by 2739.22% in 2022.
  • Over the past 5 years, Protagonist Therapeutics' Cash & Current Investments (Quarter) stood at $326.9 million in 2021, then fell by 27.39% to $237.4 million in 2022, then surged by 43.93% to $341.6 million in 2023, then increased by 22.63% to $418.9 million in 2024, then soared by 37.51% to $576.1 million in 2025.
  • Its Cash & Current Investments was $576.1 million in Q3 2025, compared to $570.5 million in Q2 2025 and $574.4 million in Q1 2025.